Cellceutix Corp. (CTIX.OB) reported that it has been conducting meetings with manufacturers to synthesize and formulate its lead psoriasis drug, Prurisol, for a Phase 2/3 clinical trial.
Cellceutix said the U.S. Food and Drug Administration recently told the company that an application for a 505(b)(2) designation for Prurisol would be an acceptable approach; allowing the Company to advance Prurisol immediately into advanced stages of clinical trials.
Click here to receive FREE breaking news email alerts for Cellceutix Corp and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com